Central sleep apnea after interrupting longterm acetazolamide therapy.

Abstract

One month administration of acetazolamide (ACET) (at sea level) improves periodic breathing and decreases the number of central apneas (CA) (De Backer et al., 1995 Am. J. Respir. Crit. Care Med. 151, 87-91) in nonhypercapnic central apnea syndrome. It remains unclear whether cessation of therapy would provoke recurrence of symptoms. In the present study we evaluated the number of CA after 1 and 6 months interruption of ACET therapy. Eight patients with central sleep apnea were included [central apnea index (CAI) > 5 or apnea and hypopnea index (AHI) > 10 and obstructive apnea index (OAI) < 5]. Polysomnography was repeated once after 1 month treatment (N2), after 1 month off treatment (N3) and after 6 months off treatment. CAI (25 +/- 10 at N1) decreased during N2 (4 +/- 2) and N3 (5 +/- 3) and remained low after N4 (3 +/- 1). However an increase in the number of obstructive apneas and central hypopneas could be observed together with a shift from central apnea to hypopnea after N4. Maybe ACET induces a long lasting resetting of the CO2 threshold which is still present after interruption of the therapy.

• Authors: J Verbraecken, M Willemen, W De Cock, E Coen, P Van de Heyning, W De Backer
• Journal: Respiration physiology (Respir Physiol) Vol. 112 Issue 1 Pg. 59-70 (Apr 1998) ISSN: 0034-5687 [Print] Netherlands
• PMID: 9696283 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Acetazolamide

Topics

• Acetazolamide (administration & dosage, therapeutic use)
• Adult
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Respiration (drug effects)
• Sleep Apnea Syndromes (drug therapy)